Adenosine receptors and asthma in humans

British Journal of Pharmacology

Volumn 155, Issue 4, 2008, Pages 475-486

  Wilson, C N ^a  

^a Endacea Inc   (United States)

Author keywords

A 1 AR; A 2a AR; A 2b AR; A 3 AR; Adenosine; ARs; Asthma

Indexed keywords

2 [4 (2 CARBOXYETHYL)PHENETHYLAMINO]ADENOSINE 5' (N ETHYLCARBOXAMIDE); 3 [4 (2,3,6,7 TETRAHYDRO 2,6 DIOXO 1,3 DIPROPYL 1H PURIN 8 YL)BICYCLO[2.2.2]OCTAN 1 YL]PROPIONIC ACID; 4 [3 [6 AMINO 9 (5 ETHYLCARBAMOYL 3,4 DIHYDROXYTETRAHYDRO 2 FURYL) 9H PURIN 2 YL] 2 PROPYNYL]CYCLOHEXANECARBOXYLIC ACID METHYL ESTER; 6 N (3 IODOBENZYL)ADENOSINE 5' N METHYLCARBOXAMIDE; 8 (2 NOR 1 ADAMANTYL) 1,3 DIPROPYLXANTHINE; ADENOSINE A1 RECEPTOR; ADENOSINE A2A RECEPTOR; ADENOSINE A2A RECEPTOR AGONIST; ADENOSINE A2B RECEPTOR; ADENOSINE A3 RECEPTOR; ADENOSINE A3 RECEPTOR ANTAGONIST; ADENOSINE RECEPTOR; ATL 313; CF 102; CVT 6883; EPI 2010; FLUTICASONE; G PROTEIN COUPLED RECEPTOR; GW 328267X; INTERLEUKIN 6; L 97 1; MRE 0094; MRS 1706; QAF 805; SLV 320; UK 432097; UNCLASSIFIED DRUG;

ASTHMA; BRONCHUS MUCOSA; BRONCHUS MUSCLE; CHRONIC INFLAMMATION; CORTICOSTEROID THERAPY; DRUG RECEPTOR BINDING; HEPATITIS; HISTOPATHOLOGY; HUMAN; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS;

ADENOSINE; ANIMALS; ANTI-ASTHMATIC AGENTS; ASTHMA; CLINICAL TRIALS AS TOPIC; DRUG DELIVERY SYSTEMS; DRUG DESIGN; HUMANS; PURINERGIC P1 RECEPTOR AGONISTS; PURINERGIC P1 RECEPTOR ANTAGONISTS; RECEPTORS, PURINERGIC P1; SIGNAL TRANSDUCTION;

EID: 53849085809     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/bjp.2008.361     Document Type: Review

References (101)

1. Abbrachio MP, Cattabeni F (1987). Selective activity of bamiphylline on adenosine A1 - receptors in rat brain. Pharmacol Res 19: 537-545.
2. 2a adenosine receptors in human cells and their interactions. Biochem Biophys Res Commun 208: 871-878.
3. Akbar M, Okajima F, Tomura H, Shimegi S, Kondo Y (1994). A single species of A1 adenosine receptor expressed in chinese hamster ovary cells not only inhibits cAMP accumulation but also stimulates phospholipase C and arachidonate release. Molecular Pharmacol 45: 1036-1042.
4. Ball HA, Sandrasagra A, Tang L, Scott MV, Wild J, Nyce JW (2003). Clinical potential of respirable antisense oligonucleotides (RASONs) in asthma. Am J Pharmacogenomics 3: 97-106.
5. Baraldi PG, Cacciari B, Romagnoli R, Merighi S, Varani K, Borea PA et al. (2000). A3 adenosine receptor ligands: history and perspectives. Med Res Rev 20: 103-128.
6. Barnes PJ (2003). Theophylline: New Perspectives for an old drug. Am J Resp Crit Care Med 167: 813-818.
7. Barrett RJ (1996). Realizing the potential of adenosine-receptor-based therapeutics. Proc West Pharmacol Soc 39: 61-66.
8. Bender BG, Rand C (2004). Medication non-adherence and asthma treatment cost. Curr Opin Allergy Clin Immunol 4: 191-195.
9. Bertolet BD, Belardinelli L, Franco EA, Nichols WW, Kerensky RA, Hill JA (1996). Selective attenuation by N-0861 (N6-Endonorboran-2-yl-9-methyladenine) of cardiac A1 adenosine receptormediated effects in humans. Circulation 93: 1871-1876.
10. Bjorck T, Gustafsson LE, Dahlen S-E (1992). Isolated bronchi from asthmatics are hyper responsive to adenosine, which apparently acts indirectly by liberation of leukotrienes and histamine. Am Rev Respir Dis 145: 1087-1091.
11. Breschi MC, Blandizzi C, Fogli S, Martinelli C, Adinolfi B, Calderone V et al. (2007). In vivo adenosine A(2B) receptor desensitization in guinea-pig airway smooth muscle: implications for asthma. Eur J Pharmacol 575: 149-157.
12. Brown RA, Clarke GW, Ledbetter CL, Hurle MJ, Denyer JC, Simcock DE et al. (2008). Elevated expression of adenosine A1 receptor in bronchial biopsies from asthmatic subjects. European Respir J 31: 1-9.
13. Catena E, Gunella G, Monici PPA, Oliani C (1988). Evaluation of the risk/benefit ratio of bamiphylline in the treatment of chronic obstructive lung disease. Italian J Chest Dis 42: 419-426.
14. Ciruela F, Saura C, Canela EI, Mallol J, Lluis C, Franco R (1996). Adenosine deaminase affects ligand-induced signalling by interacting with cell surface adenosine receptors. FEBS Lett 380: 219-223.
15. Clancy JP, Ruiz FE, Sorscher EJ (1999). Adenosine and its nucleotides activate wild-type and R117H CFTR through an A2B receptor-coupled pathway. Am J Physiol 276 (2 Pt. 1): C361-C369.
16. Clark AN, Youkey R, Liu X, Jia L, Blatt R, Day YJ et al. (2007). A1 adenosine receptor activation promotes angiogenesis and release of VEGF from monocytes. Circ Res 101: 1130-1138.
17. Cohn L, Elias JA, Chupp GL (2004). Asthma: mechanisms of disease persistence and progression. Annu Rev Immunol 22: 789-815.
18. Crescioli S, Spinazzi A, Plebani M, Pozzani M, Mapp CE, Boschetto P et al. (1991). Theophylline inhibits early and late asthmatic reactions induced by allergens in asthmatic subjects. Ann Allergy 66: 245-251.
19. Cronstein BN (2006). Adenosine receptors and wound healing, revised. Scientific World J 6: 984-991.
20. Cronstein BN, Daguma L, Nichols D, Hutchison AJ, Williams M (1990). The adenosine/neutrophil paradox resolved: human neutrophils possess both A1 and A2 receptors that promote chemotaxis and inhibit O2 generation, respectively. J Clin Invest 85: 1150-1157.
21. Cronstein BN, Levin RI, Phillips M, Hirschhorn R, Abramson SB, Weissman G (1992). Neutrophil adherence to endothelium is enhanced via adenosine A1 receptors and inhibited via adenosine A2 receptors. J Immunol 148: 2201-2206.
22. Cushley MJ, Tattersfield AE, Holgate ST (1983). Inhaled adenosine and guanosine on airway resistance in normal and asthmatic subjects. Br J Clin Pharmacol 15: 161-165.
23. Dahlen S-E, Hansson G, Hedqvist P, Bjorck T, Granstrom E, Dahlen B (1983). Allergen challenge of lung tissue from asthmatics elicits bronchial contraction that correlates with the release of leukotrienes C4, D4, and E4. Proc Natl Acad Sci USA 80: 1712-1716.
24. de Meer G, Heederik D, Postma DS (2002). Bronchial responsiveness to adenosine 5′-monophosphate (AMP) and methacholine differ in their relationship with airway allergy and baseline FEV1. Am J Respir Crit Care Med 165: 327-331.
25. Dittrich HC, Gupta DK, Hack TC, Dowling T, Callahan J, Thomson S (2007). The effect of KW-3902, an adenosine A1 receptor antagonist, on renal function and renal plasma flow in ambulatory patients with heart failure and renal impairment. J Card Failure 13: 609-617.
26. Doggrell SA (2005). BG-9928 Biogen Idec. Curr Opin Investig Drugs 6: 962-968.
27. Driver AG, Kukoly CA, Ali S, Mustafa SJ (1993). Adenosine in bronchoalveolar lavage fluid in asthma. Am Rev Respir Dis 148: 91-97.
28. Ethier MF, Madison JM (2006). Adenosine A1 receptors mediate mobilization of calcium in human bronchial smooth muscle cells. Am J Respir Cell Mol Biol 35: 496-502.
29. Feoktistov I, Biaggioni I (1995). Adenosine A2b receptors evoke interleukin-8 secretion in human mast cells: an enprofylline-sensitive mechanism with implications for asthma. J Clin Invest 96: 1979-1986.
30. Feoktistov I, Goldstein AE, Ryzhov S, Zeng D, Belardinelli L, Maa T et al. (2002). Differential expression of adenosine receptors in human endothelial cells: role of A2b receptors in angiogenic factor regulation. Circ Res 90: 531-538.
31. Fishman P, Bar-Yehuda S (2003). Pharmacology and therapeutic applications of A3 receptor subtype. Curr Topics Med Chem 3: 463-469.
32. Forsythe P, McGarvey LPA, Heaney LG, MacMahon J, Ennis M (1999). Adenosine induces histamine release from human bronchoalveolar lavage mast cells. Clin Sci 96: 349-355.
33. Foutillan JP, Lefebvre MA, Ingrand I (1983). Pharmacokinetic study of bamiphylline (and metabolites) in healthy volunteers using chromatography and mass spectrometry. Therapie 38: 647-658.
34. Fozard JR, Ellis KM, Villela Dantas MF, Tigani B, Mazzoni L (2002). Effects of CGS 21680, a selective adenosine A2A receptor agonist, on allergic airways inflammation in the rat. Eur J Pharmacol 438: 183-188.
35. Fredholm BB (2003). Adenosine receptors as targets for drug development. Drug News Perspect 16: 283-289.
36. Fredholm BB, Ijzerman AP, Jacobson KA, Klotz K-N, Linden J (2001). International union of pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol Rev 53: 527-552.
37. Gaspardone A, Crea F, Iamele M, Tomai F, Versaci F, Pellegrino A et al. (1993). Bamiphylline improves exercise-induced myocardial ischemia through a novel mechanism of action. Circulation 88: 502-508.
38. Gessi S, Merighi S, Varani K, Leung E, Lennan SM, Borea PA (2008). The A3 adenosine receptor: an enigmatic player in cell biology. Pharmacol Ther 117: 123-140.
39. Ginesu F, Chessa G, Deiola G, Ortu AF, Santoru L, Peana GP (1987). Controlled clinical study on activity and tolerability of a new xanthine derivative. Italian J Chest Dis 41: 311-316.
40. Givertz MM, Massie BM, Fields TK, Pearson LL, Dittrich HC (2007). The effect of KW-3902, an adenosine A1-receptor antagonist, on diuresis and renal function in patients with acute decompensated heart failure and renal impairment or diuretic resistance. J Am Coll Cardiol 50: 1551-1560.
41. Gottlieb SS, Brater C, Thomas I, Havranek E, Bourge R, Goldman S et al. (2002). BG9719 (CVT-124), an A1 adenosine receptor antagonist, protects against the decline in renal function observed with diuretic therapy. Circulation 105: 1348-1353.
42. Greenberg B, Ignatius T, Banish D, Goldman S, Havranek E, Massie BM et al. (2007). Effects of multiple oral doses of an A1 adenosine receptor antagonist, BG 9928, in patients with heart failure. J Am Coll Cardiol 50: 600-606.
43. Hasko G, Cronstein BN (2004). Adenosine: an endogenous regulator of innate immunity. Trends in Immunol 25: 33-39.
44. Holgate ST (2002). Adenosine provocation: a new test for allergic type airway inflammation. Am J Respir Crit Care Med 165: 317-319.
45. Huang P, Lazarowski ER, Tarran R, Milgram SL, Boucher RC, Stutts MJ (2001). Compartmentalized autocrine signaling to cystic fibrosis transmembrane conductance regulator at the apical membrane of airway epithelial cells. Proc Natl Acad Sci USA 98: 14120-14125.
46. Huszar E, Vass G, Vizi E, Csoma Z, Barat E, Molnar VG et al. (2002). Adenosine in exhaled breath condensate in healthy volunteers and in patients with asthma. Eur Respir J 20: 1393-1398.
47. Jarjour NN, Kelly EAB (2002). Pathogenesis of asthma. Med Clin North Am 86: 925-936.
48. Jones C, Santanello NC, Boccuzzi SJ, Wogen J, Strub P, Nelsen LM (2003). Adherence to prescribed treatment for asthma: evidence from pharmacy benefits data. J Asthma 40: 93-101.
49. Knight D, Zheng X, Rocchini C, Jacobson M, Bai T, Walker B (1997). Adenosine A3 receptor stimulation inhibits migration of human eosinophils. J Leukoc Biol 62: 465-468.
50. Kolachala VL, Obertone TS, Wang L, Merlin D, Sitaraman SV (2006). Adenosine A2b receptor (A2bR) signals through adenylate cyclase (AC) 6 isoform in the intestinal epithelial cells. Biochim Biophys Acta 1760: 1102-1108.
51. Lai D-M, Tu Y-K, Liu I-M, Cheng J-T (2005). Increase of adenosine A1 receptor gene expression in cerebral ischemia of Wistar rats. Neurosci Lett 387: 59-61.
52. Langley SJ, Allen DJ, Houghton C, Woodcock A (2005). Efficacy of EPI-2010 (An inhaled respirable anti-sense oligonucleotide: RASON) in moderate/severe persistent asthma. Am J Resp Crit Care Med 171: A360.
53. Lennon PF, Taylor CT, Stahl GL, Colgan SP (1998). Neutrophil-derived 5′-adenosine monophosphate promotes endothelial barrier function via CD73-mediated conversion to adenosine and endothelial A2B receptor activation. J Exp Med 188: 1433-1443.
54. Livingston M, Heaney LG, Ennis M (2004). Adenosine, inflammation, and asthma-a review. Inflamm Res 53: 171-178.
55. Luijk B, van den Berge M, Kerstjens HAM, Postma DS, Cass L, Sabin A et al. (2008). Effect of an inhaled adenosine A2A agonist on the allergen-induced late asthmatic response. Allergy 63: 75-80.
56. Marone G, Petracca R, Vigorita S, Genovese A, Casolaro V (1992). Adenosine receptors on human leukocytes. IV. Characterization of an A1/Ri receptor. Int J Clin Lab Res 22: 235-242.
57. Marquardt DL (1997). Adenosine. In: Barnes PJ, Grunstein MM, Leff AR, Woolcock AJ (eds). Asthma. Lippincott-Raven Publishers: Philadelphia, PA. pp 585-591.
58. Masoli M, Fabian D, Holt S, Beasley R, for the Global Initiative for Asthma (GINA) Program (2004). The global burden of asthma: executive summary of the GINA dissemination committee report. Allergy 59: 469-478.
59. McNamara N, Gallup M, Khong A, Sucher A, Maltseva I, Fahy JVet al. (2004). Adenosine up-regulation of the mucin gene, MU2, in asthma. FASEB J 18: 1770-1772.
60. Montesinos MC, Shaw JP, Yee H, Shamamian P, Cronstein BN (2006). Adenosine A(2A) receptor activation promotes wound neovascularization by stimulating angiogenesis and vasculogenesis. Am J Pathol 164: 1887-1892.
61. Montesinos MC, Gadangi P, Longaker M, Sung J, Levine J, Nilsen D et al. (1997). Wound healing is accelerated by agonists of adenosine A2 (Gs-linked) receptors. J Exp Med 186: 1615-1620.
62. Morandini G (1988). Multicentre trial on the efficacy and tolerability of bamiphylline in the treatment of patients with COLD. La Presse Medicale 3: 1-10.
63. Murakami S, Hashikawa T, Saho T, Takedachi M, Nozaki T, Shimabukuro Y et al. (2001). Adenosine regulates the IL-1β-induced cellular functions of human gingival fibroblasts. International Immunol 13: 1533-1540.
64. Mustafa SJ, Nadeem A, Fan M, Zhong H, Belardinelli L, Zeng D (2007). Effect of a specific and selective A(2B) adenosine receptor antagonist on adenosine agonist AMP and allergen-induced airway responsiveness and cellular influx in a mouse model of asthma. J Pharmacol Exp Ther 320: 1246-1251.
65. Nadeem A, Mustafa SJ (2006). Adenosine receptor antagonists and asthma. Drug Discovery Today:Ther Stratagies 3: 269-275.
66. Nadeem A, Obiefuna PC, Wilson CN, Mustafa SJ (2006). Adenosine A1 receptor antagonist versus montelukast on airway reactivity and inflammation. E J Pharmacol 551: 116-124.
67. Nilsson G, Blom T, Kusche-Gullberg M, Kjellen L, Butterfield JH, Sundstrom C et al. (1994). Phenotypic characterization of the human mast cell line HMC-1. Scand J Immunol 39: 489-498.
68. Obiefuna PC, Batra VK, Nadeem A, Borron P, Wilson CN, Mustafa SJ (2005). A Novel A1 Adenosine Receptor Antagonist, L-97-1, [3-[2-(4-Aminophenyl)-ethyl]- 8-benzyl-7-{2-[ethyl-(2-hydroxy-ethyl)-amino]-ethyl}-1-propyl-3, 7-dihydro-purine-2,6-dione], Reduces Allergic Responses to House Dust Mite in an Allergic Rabbit Model of Asthma. J Pharmacol Exp Ther 315: 329-336.
69. Ohta A, Gorelik E, Prasad SJ, Ronchese F, Lukashev D,Wong MK et al. (2006). A2A adenosine receptor protects tumors from antitumor T cells. Proc Natl Acad Sci USA 103: 3132-13137.
70. Olah ME, Stiles GL (2000). The role of receptor structure in determining adenosine receptor activity. Pharmacol Ther 85: 55-75.
71. Panther E, Idzko M, Herouy Y, Rheinen H, Gebicke-Haerter PJ, Mrowietz U et al. (2001). Expression and function of adenosine receptors in human dendritic cells. FASEB J 15: 1963-1970.
72. Pascoe SJ, Knight H, Woessner R (2007). QAF805, an A2b/A3 adenosine receptor antagonist does not attenuate AMP challenge in subjects with asthma. Am J Resp Crit Care Med 175: A682.
73. Peachell PT, Columbo M, Kagey-Sobotka A, Lichtenstein LM, Marone G (1998). Adenosine potentiates mediator release from human lung mast cells. Am Rev Respir Dis 138: 1143-1151.
74. Polosa R (2002). Adenosine-receptor subtypes: their relevance to adenosine-mediated responses in asthma and chronic obstructed pulmonary disease. Eur Respir J 20: 488-496.
75. Rogachev B, Ziv NY, Mazar J, Nakav S, Chaimovitz C, Zlotnik M et al. (2006). Adenosine is upregulated during peritonitis and is involved in downregulation of inflammation. Kidney Internal 70: 675-681.
76. Rollins BM, Burn M, Coakley RD, Chambers LA, Hirsh AJ, Clunes MT et al. (2008). A2B adenosine receptors regulate the mucus clearance component of the lungs innate defense system. Am J Respir Cell Mol Biol 39: 190-197.
77. Rorke S, Holgate ST (2002). Targeting adenosine receptors: novel therapeutic targets in asthma and chronic obstructive pulmonary disease. Am J Respir Med 1: 99-105.
78. Russo C, Arcidiacono G, Polosa R (2006). Adenosine receptors: promising targets for the development of novel therapeutics and diagnostics for asthma. Fund Clin Pharmacol 20: 9-19.
79. Ryzhov S, Goldstein AE, Matafonov A, Zeng D, Biaggioni I, Feoktistov I (2004). Adenosine-activated mast cells induce IgE synthesis by B lymphocytes: an A2B-mediated process involving Th2 cytokines IL-4 and IL-13 with implications for asthma. J Immunol 172: 7726-7733.
80. Ryzhov S, Zaynagetdinov R, Goldstein AE, Novitskiy SV, Blackburn MR, Biaggioni I et al. (2008). Effect of A2B adenosine receptor gene ablation on adenosine-dependent regulation of proinflammatory cytokines. J Pharmacol Exp Ther 324: 694-700.
81. Salmon JE, Brogle N, Brownlie C, Edberg JC, Kimberly RP, Chen BX et al. (1993). Human mononuclear phagocytes express adenosine A1 receptors. A novel mechanism for differential regulation of Fc gamma receptor function. J Immunol 151: 2775-2785.
82. Salmon JE, Cronstein BN (1990). Fc gamma receptor-mediated functions in neutrophils are modulated by adenosine receptor occupancy. A1 receptors are stimulatory and A2 receptors are inhibitory. J Immunol 145: 2235-2240.
83. Salpeter SR, Ormiston TM, Salpeter EE (2004). Cardiovascular effects of beta-agonists in patients with asthma and COPD: a metanalysis. Chest 125: 2309-2321.
84. Saura C, Ciruela F, Casadó V, Canela EI, Mallol J, Lluis C et al. (1996). Adenosine deaminase interacts with A1 adenosine receptors in pig brain cortical membranes. J Neurochem 66: 1675-1682.
85. Silva GE, Sherrill DL, Guerra S, Barbee RA (2004). Asthma as a risk factor for COPD in a longitudinal study. Chest 126: 59-65.
86. Sin DD, Man J, Sharpe H, Gan WQ, Man SFP (2004). Pharmacological management to reduce exacerbations in adults with asthma. JAMA 292: 367-376.
87. Spicuzza L, Bonfiglio C, Polosa R (2003). Research applications and implications of adenosine in diseased airways. Trends in Pharmacol Sciences 24: 409-413.
88. Spruntulis LM, Broadley KJ (2001). A3 receptors mediate rapid inflammatory cell influx into the lungs of sensitized guinea-pigs. Clin Exp Allergy 31: 943-951.
89. Strohmeier GR, Reppert SM, Lencer WI, Madara JL (1995). The A2b adenosine receptor mediates cAMP responses to adenosine receptor agonists in human intestinal epithelia. J Biol Chem 270: 2387-2394.
90. Sullivan GW (2003). Adenosine A2A receptor agonists as antiinflammatory agents. Curr Opin Investig Drugs 4: 1313-1319.
91. Sun CX, Young HW, Molina JG, Volmer JB, Schnermann J, Blackburn MR (2005). A protective role for the A1 adenosine receptor in adenosine-dependent pulmonary injury. J Clin Invest 115: 35-43.
92. Sun C-X, Zhong H, Mohsenin A, Morschl E, Chunn JL, Molina JG et al. (2006). Role of A2B adenosine receptor signaling in adenosine-dependent pulmonary inflammation and injury. J Clin Invest 116: 2173-2182.
93. van Galen PJM, Stiles GL, Michaels G, Jacobson KA (1992). Adenosine A1 and A2 receptors: structure-function relationships. Medicinal Res Rev 12: 423-471.
94. van Troostenburg A-R, Clark EV, Carey WDH, Warrington SJ, Kerns WD, Cohn I et al. (2004). Tolerability, pharmacokinetics and concentration- dependent hemodynamic effects of oral CF 101, an A3 adenosine receptor agonist, in healthy young men. Internat J Clin Pharmacol Ther 42: 534-542.
95. Vizi E, Huzzar E, Csoma Z, Boszormenyi-Nagy G, Barat E, Horvath I et al. (2002). Plasma adenosine concentration increases during exercise: a possible contributing factor in exercise-induced bronchoconstriction in asthma. J Allergy Clin Immunol 109: 446-448.
96. Webb RL, Sills MA, Chovan JP, Peppard JV, Francis JE (1993). Development of tolerance to the antihypertensive effects of highly selective adenosine A2a agonists upon chronic administration. J Pharmacol Exp Ther 267: 287-295.
97. Wilson CN, Batra VK (2002). Lipopolysaccharide binds to and activates A1 adenosine receptors on human pulmonary artery endothelial cells. J Endotoxin Res 8: 263-271.
98. Yang D, Zhang Y, Nguyen HG, Koupenova M, Chauhan AK, Makitalo M et al. (2006). The A2B adenosine receptor protects against inflammation and excessive vascular adhesion. J Clin Invest 116: 1913-1923.
99. Zhong H, Belardinelli L, Maa T, Feoktistov I, Biaggioni I, Zeng D (2004). A2b adenosine receptors increase cytokine release by bronchial smooth muscle cells. Am J Resp Cell Mol Biol 30: 118-125.
100. Zhong H, Belardinelli L, Maa T, Zeng D (2005). Synergy between A2b adenosine receptors and hypoxia in activating human lung fibroblasts. Am J Respir Cell Mol Biol 32: 2-8.
101. Zhong H, Wu Y, Belardinelli L, Zeng D (2006). A2B adenosine receptors induce IL-19 from bronchial epithelial cells, resulting in TNF-alpha increase. Am J Resp Cell Mol Biol 35: 587-592.